Relapsed Refractory Multiple Myeloma Clinical Trial
Official title:
Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study
To characterize safety associated with the use of Kyprolis under the locally approved label.
Kyprolis® (K; carfilzomib) was approved in India on 17 January 2017 as a prescription medication in combination with dexamethasone (Kd) or with lenalidomide (Revlimid®) plus dexamethasone (KRd) for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) following 1 to 3 prior lines of therapy. This non-comparative, interventional phase 4 study is designed to fulfil the post-marketing requirement to assess safety, tolerability, and efficacy of Kyprolis on Indian subjects with RRMM as per the locally approved label. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04065425 -
Phase I/II Assessment of Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04150965 -
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
|
Phase 1/Phase 2 | |
| Completed |
NCT00697684 -
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
|
Phase 1 | |
| Suspended |
NCT04505813 -
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03732703 -
Myeloma-Developing Regimens Using Genomics (MyDRUG)
|
Phase 1/Phase 2 |